Abstract
Women going through menopause frequently experience vasomotor symptoms such as hot flashes, night sweats, and sleep disturbances, significantly influencing their quality of life. Hormonal therapy has been demonstrated to be beneficial in treating VMS. However, due to specific restrictions, it is not recommended for every woman. Fezolinetant, a neurokinin 3 antagonist and non-hormonal treatment for severe to moderate VMS, functions by inhibiting neuronal impulses originating from the hypothalamic thermoregulatory center. Current Skylight 2 and 4 trials statistically demonstrate the safety and acceptability of fezolinetant, with relatively few adverse effects reported. Fezolinetant has been shown great potential for treating menopausal-related VMS, supporting its further advancement. However, further investigation is required to thoroughly evaluate its safety, effectiveness, and its impact on sleep patterns.
This is a preview of subscription content, log in via an institution to check access.
References
Amgen F (2010) Center for Drug Evaluation and Research Cenobamate Clinical Review. Clin Rev, 0–13
David PS, Smith TL, Nordhues HC, Kling JM (2022) A clinical review on paroxetine and emerging therapies for the treatment of vasomotor symptoms. Int J Women’s Health 14:353–361. https://doi.org/10.2147/IJWH.S282396
Depypere H, Lademacher C, Siddiqui E, Fraser GL (2021) Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs 30(7):681–694. https://doi.org/10.1080/13543784.2021.1893305
FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause | FDA. (n.d.). Retrieved June 20, (2023) from https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause
Fraser GL, Lederman S, Waldbaum A, Kroll R, Santoro N, Lee M, Skillern L, Ramael S (2020) A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause 27(4):382–392. https://doi.org/10.1097/GME.0000000000001510
Fraser GL, Obermayer-Pietsch B, Laven J, Griesinger G, Pintiaux A, Timmerman D, Fauser BCJM, Lademacher C, Combalbert J, Hoveyda HR, Ramael S (2021) Randomized controlled trial of Neurokinin 3 receptor antagonist fezolinetant for treatment of polycystic ovary syndrome. J Clin Endocrinol Metab 106(9):e3519. https://doi.org/10.1210/CLINEM/DGAB320
Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K (2006) Longitudinal Analysis of the Association between Vasomotor Symptoms and Race/Ethnicity across the Menopausal Transition: study of women’s Health across the Nation. Am J Public Health 96(7):1226–1235. https://doi.org/10.2105/AJPH.2005.066936
Huang AJ, Cummings SR, Ganz P, Schembri M, Raghunathan H, Vittinghoff E, Gibson CJ, Grady D (2023) Efficacy of continuous Transdermal nitroglycerin for treating hot flashes by inducing nitrate cross-tolerance in Perimenopausal and Postmenopausal women. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2023.1977
Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C, Lee M, Santoro N (2023) Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms Associated with Menopause: a phase 3 RCT. J Clin Endocrinol Metabolism. https://doi.org/10.1210/CLINEM/DGAD058
Menown SJ, Tello JA (2021) Neurokinin 3 receptor antagonists compared with serotonin norepinephrine reuptake inhibitors for non-hormonal treatment of menopausal hot flushes: a systematic qualitative review. Adv Therapy 38(10):5025–5045. https://doi.org/10.1007/s12325-021-01900-w
Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD (2023) Safety of fezolinetant for vasomotor symptoms Associated with Menopause. Obstet Gynecol 141(4):737–747. https://doi.org/10.1097/AOG.0000000000005114
Santoro N, Waldbaum A, Lederman S, Kroll R, Fraser GL, Lademacher C, Skillern L, Young J, Ramael S (2020) Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Menopause (New York N Y) 27(12):1350. https://doi.org/10.1097/GME.0000000000001621
Funding
No funding was acquired for this paper.
Author information
Authors and Affiliations
Contributions
Priya Rani: Conceptualization, writing – original draft, final approval and agreeing to the accuracy of the work.
Dua Zehra: Writing – original draft, final approval and agreeing to the accuracy of the work.
Malaika Mansoor: Writing – original draft, final approval and agreeing to the accuracy of the work.
Payal Rani: Writing – original draft, final approval and agreeing to the accuracy of the work.
Corresponding author
Ethics declarations
Ethical approval
Ethical approval is not required or applicable for this manuscript type as no human participants or animals were involved.
Consent statement
The study was not done on patients or volunteers, therefore no written consent was required.
Conflict of interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rani, P., Zehra, D., Mansoor, M. et al. FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research. Arch Womens Ment Health (2024). https://doi.org/10.1007/s00737-024-01456-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00737-024-01456-y